We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Chemed (CHE) Up 9.3% Since Last Earnings Report?
Read MoreHide Full Article
It has been about a month since the last earnings report for Chemed (CHE - Free Report) . Shares have added about 9.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Chemed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Chemed Misses Q2 Earnings Estimates
Chemed Corporation reported second-quarter 2025 adjusted earnings per share of $4.27, down 21.9% year over year. The figure fell short of the Zacks Consensus Estimate by 10.67%.
The company’s GAAP earnings per share were $3.57, down 23.2% from last year’s reported figure.
Chemed’s Q2 Revenues
Revenues in the reported quarter improved 3.8% year over year to $618.8 million. The metric topped the Zacks Consensus Estimate by 0.45%.
Chemed Updates 2025 Guidance
The company revised its full-year 2025 guidance. Revenues from VITAS, before Medicare Cap, are now estimated to increase 7.5% to 8.5% (earlier 10.5% to 11.3%) from the 2024 levels.
The Zacks Consensus Estimate for total revenues is pegged at $2.55 billion, which indicates a 4.9% improvement year over year.
Adjusted earnings are anticipated in the range of $22.00-$22.30 per share (previously $24.95-$25.45 range). The Zacks Consensus Estimate for the metric is pegged at $22.12, which implies a 4.4% fall over the 2024 adjusted figure.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
The consensus estimate has shifted -5.56% due to these changes.
VGM Scores
At this time, Chemed has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Chemed has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Chemed belongs to the Zacks Medical - Outpatient and Home Healthcare industry. Another stock from the same industry, Quest Diagnostics (DGX - Free Report) , has gained 6.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025.
Quest Diagnostics reported revenues of $2.76 billion in the last reported quarter, representing a year-over-year change of +15.2%. EPS of $2.62 for the same period compares with $2.35 a year ago.
Quest Diagnostics is expected to post earnings of $2.51 per share for the current quarter, representing a year-over-year change of +9.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.1%.
Quest Diagnostics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Chemed (CHE) Up 9.3% Since Last Earnings Report?
It has been about a month since the last earnings report for Chemed (CHE - Free Report) . Shares have added about 9.3% in that time frame, outperforming the S&P 500.
Will the recent positive trend continue leading up to its next earnings release, or is Chemed due for a pullback? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at the most recent earnings report in order to get a better handle on the important drivers.
Chemed Misses Q2 Earnings Estimates
Chemed Corporation reported second-quarter 2025 adjusted earnings per share of $4.27, down 21.9% year over year. The figure fell short of the Zacks Consensus Estimate by 10.67%.
The company’s GAAP earnings per share were $3.57, down 23.2% from last year’s reported figure.
Chemed’s Q2 Revenues
Revenues in the reported quarter improved 3.8% year over year to $618.8 million. The metric topped the Zacks Consensus Estimate by 0.45%.
Chemed Updates 2025 Guidance
The company revised its full-year 2025 guidance. Revenues from VITAS, before Medicare Cap, are now estimated to increase 7.5% to 8.5% (earlier 10.5% to 11.3%) from the 2024 levels.
The Zacks Consensus Estimate for total revenues is pegged at $2.55 billion, which indicates a 4.9% improvement year over year.
Adjusted earnings are anticipated in the range of $22.00-$22.30 per share (previously $24.95-$25.45 range). The Zacks Consensus Estimate for the metric is pegged at $22.12, which implies a 4.4% fall over the 2024 adjusted figure.
How Have Estimates Been Moving Since Then?
It turns out, estimates revision have trended downward during the past month.
The consensus estimate has shifted -5.56% due to these changes.
VGM Scores
At this time, Chemed has a great Growth Score of A, though it is lagging a lot on the Momentum Score front with a C. Charting a somewhat similar path, the stock has a score of D on the value side, putting it in the bottom 40% for value investors.
Overall, the stock has an aggregate VGM Score of B. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Estimates have been broadly trending downward for the stock, and the magnitude of these revisions indicates a downward shift. It's no surprise Chemed has a Zacks Rank #5 (Strong Sell). We expect a below average return from the stock in the next few months.
Performance of an Industry Player
Chemed belongs to the Zacks Medical - Outpatient and Home Healthcare industry. Another stock from the same industry, Quest Diagnostics (DGX - Free Report) , has gained 6.5% over the past month. More than a month has passed since the company reported results for the quarter ended June 2025.
Quest Diagnostics reported revenues of $2.76 billion in the last reported quarter, representing a year-over-year change of +15.2%. EPS of $2.62 for the same period compares with $2.35 a year ago.
Quest Diagnostics is expected to post earnings of $2.51 per share for the current quarter, representing a year-over-year change of +9.1%. Over the last 30 days, the Zacks Consensus Estimate has changed -0.1%.
Quest Diagnostics has a Zacks Rank #3 (Hold) based on the overall direction and magnitude of estimate revisions. Additionally, the stock has a VGM Score of A.